Evidence map›Paper›PMID 39136469›Full record

ArticleAntimicrobial agents and chemotherapy2024

Pratap Vydyam, Meenal Chand, Shalev Gihaz, Isaline Renard, Gavin D Heffernan, Laura R Jacobus, David P Jacobus, Kurt W Saionz, Raju Shah, Hong-Ming Shieh and 4 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Evaluating acridones as novel therapeutics for human babesiosis.Antimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Pratap VydyamDepartments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-4944-6006
Meenal ChandDepartments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
Shalev GihazDepartments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
Isaline RenardDepartments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.
Gavin D HeffernanJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
Laura R JacobusJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
David P JacobusJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
Kurt W SaionzJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
Raju ShahJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
Hong-Ming ShiehJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
Jacek TerpinskiJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
Wenyi ZhaoJacobus Pharmaceutical Company Inc., Princeton, New Jersey, USA.
Emmanuel CornillotInstitut de Biologie Computationnelle (IBC), and Institut de Recherche en Cancérologie de Montpellier (IRCM - INSERM U1194), Institut régional du Cancer Montpellier (ICM) & Université de Montpellier, Montpellier, France.
Choukri Ben MamounDepartments of Internal Medicine (Section of Infectious Diseases), Microbial Pathogenesis, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0001-5028-1400

Funding

Hit-to-Lead Development of the Kalihinol Scaffold for Malaria TreatmentR01AI138139 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BEN MAMOUN, CHOUKRI, LE ROCH, KARINE GAELLE · 2018 to 2022
$3.6M
Development of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7M
Antigen Discovery and Vaccine Development for Human Babesia ParasitesR01AI152220 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2020 to 2024
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR44AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2020 to 2022
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR43AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2018 to 2018
$300k
NIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI138139NIAID NIH HHS R01 AI152220NIAID NIH HHS R43 AI136118NIAID NIH HHS R44 AI136118
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BabesiaErythrocytesPlasmodium falciparumTriazinesAntimalarialsBabesiosisFolic Acid AntagonistsHumansParasitic Sensitivity TestsAntimalarialsFolic Acid AntagonistsTriazinesantifolatesantiparasitic drugsapicomplexanDHFR-TSdihydrotriazinenucleotide biosynthesis

Identifiers

PMID39136469
PMCPMC11373198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.